Navigation Links
CRE Statement on "Inherent Reasonableness" for Retail Pharmacy Diabetic Supplies
Date:7/24/2012

WASHINGTON, July 24, 2012 /PRNewswire/ -- The Center for Regulatory Effectiveness' Statement, delivered at today's CMS Public Meeting on:  "Inherent Reasonableness of Medicare Fee Schedule Amounts for Non-Mail Order (Retail) Diabetic Testing Supplies," is attached in pdf here and reprinted below.  The Federal Register notice for the meeting is attached here.  Comments are due to CMS by July 30th although the date may be extended.

Statement of the:

Center for Regulatory Effectiveness

before the Centers for Medicare and Medicaid Services

Public Meeting Regarding Inherent Reasonableness of Medicare Fee Schedule Amounts for Non-Mail Order (Retail) Diabetic Testing Supplies

July 23, 2012

Introduction

I'm Bruce Levinson, Senior Vice President, Regulatory Intervention at the Center for Regulatory Effectiveness. We're a regulatory watchdog focused on ensuring agency compliance with the "good government" laws that regulate the regulators.

I would like to start by thanking CMS for holding this public meeting. This meeting is an important example of outreach activities that President Obama called for in his landmark Open Government Memorandum which directed agencies to be Transparent, Participatory and Collaborative.

CMS Does Not Have "Valid and Reliable Data" for Use in Setting Diabetic Supply Prices

CMS' Federal Register notice for this meeting stated that, according to their own rules, they must "use valid and reliable data" in determining whether a payment amount is "grossly excessive or deficient."

The competitive bidding data from the Round 1 Rebid, however, is emphatically NOT valid and reliable.  That's not CRE's view, that's the considered view of hundreds of economists and auction experts from virtually every major university.

A letter to the President signed by over 240 academicians, including several Nobel laureates, stated the following:

  • CMS competitive bidding program violates all of the principles [of President Obama's Executive Order on regulation], especially the principles of transparency and of basing regulations on the best available science. Indeed, the current program is the antithesis of science and contradicts all that is known about proper market design.

Specific problems with CMS' bidding design cited by the economists include:

  • The use of non-binding bids together with setting the price equal to the median of the winning bids provides a strong incentive for low-ball bids—submitting bids dramatically below actual cost.
  • The problems with the CMS auction grow worse upon closer inspection. The complete lack of transparency is inappropriate for a government auction.

An article published in the Quarterly Journal of Economics by researchers at the California Institute of Technology concluded:

  • The CMS auction fails to generate competitive prices of goods and fails to satisfy demand.
  • the CMS auction performs poorly as a procurement auction.
  • RESULT 5.  Prices generated in the CMS auction do not approximate the competitive price. They are significantly and consistently lower than the competitive price.
  • The challenge, for those who are unconvinced by the evidence that the CMS auction will perform poorly, is to explain why the principles seen operating so clearly in the laboratory environment will not operate when the auction is deployed in the field.

The study was financed by the Gordon and Betty Moore Foundation with additional support from a National Science Foundation grant.

The Data Quality Act and CMS' Regulatory Plans

The results from the Round 1 Rebid not only don't comply with CMS requirements for "inherent reasonableness," they also don't comply with the quality standards established by Congress and implemented by the White House Office of Management and Budget through the Data Quality Act.

The Data Quality Act provides affected parties the right to "seek and obtain" correction of information not meeting quality standards.

If anyone here would like to know more about the DQA and participating in exercising their right to "seek and obtain" correction of the Round 1 Rebid results, please see me, I'll be here through the end of the meeting.


'/>"/>
SOURCE Center for Regulatory Effectiveness
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
2. Lilly Statement on Affordable Care Act Ruling by Supreme Court
3. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in the U.S. Senate
4. Lilly Statement on PDUFA Vote by Senate
5. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in House of Representatives
6. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
7. American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA)
8. American Society of Hematology Statement on Senate Passage of Prescription Drug User Fee Act (PDUFA)
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. La Jolla Pharmaceutical Company Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray ... showcase a healthy CAGR during the forecast period ... in the global digital mobile X-Ray devices market, which is ... in 2017, expanding at a CAGR of 7% over the ... $ opportunity of more than US$ 100 Mn in 2017 ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... There is no ... Hospital, according to a special report in the May issue of Consumer Reports focused ... highest quality ranking for results achieved during and after coronary bypass and aortic valve ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... solutions, announces the continuation of its strategic partnership with and platinum sponsorship of ... nations in the safe and effective management of complex spine deformity cases, particularly ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
(Date:4/24/2017)... TX (PRWEB) , ... April 24, 2017 , ... As ... Memorial Museum today to honor the victims of the Holocaust and Nazi persecution, ... ceremonies at Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland ...
Breaking Medicine News(10 mins):